Table 2.
Unadjusted and adjusted relative risks (RRs) and 95% confidence intervals (CIs) for 25-hydroxyvitamin D [25(OH)D] and male live birth Effects of Aspirin in Gestation and Reproduction (EAGeR) trial, 2007–2011a,b.
| Among all women (n = 1094) | Among pregnancies (n = 803)c | Among live births (n = 601)d | |||||
|---|---|---|---|---|---|---|---|
| Ne | Unadjusted RR (95% CI) | Adjustedf RR (95% CI) | Unadjusted RR (95% CI) | Adjustedf RR (95% CI) | Unadjusted RR (95% CI) | Adjustedf RR (95% CI) | |
| 25(OH)D | |||||||
| per 10 ng mL−1 | 292 | 1.08 (1.00, 1.17) | 1.07 (0.99, 1.16) | 1.06 (0.98, 1.14) | 1.05 (0.98, 1.13) | 1.04 (0.95, 1.13) | 1.03 (0.95, 1.12) |
| <30 ng mL−1 (referent) | 135 | 1 | 1 | 1 | 1 | 1 | 1 |
| ≥30 ng mL−1 | 157 | 1.27 (1.04, 1.56) | 1.26 (1.03, 1.53) | 1.20 (0.98, 1.46) | 1.18 (0.97, 1.44) | 1.19 (0.94, 1.51) | 1.18 (0.94, 1.48) |
| Among hsCRP≤1.95 ng mL−1 | |||||||
| <30 ng mL−1 (referent) | 92 | 1 | 1 | 1 | 1 | 1 | 1 |
| ≥30 ng mL−1 | 118 | 1.16 (0.92, 1.47) | 1.12 (0.89, 1.41) | 1.09 (0.87, 1.37) | 1.06 (0.84, 1.32) | 1.03 (0.83, 1.29) | 1.02 (0.82, 1.27) |
| Among hsCRP>1.95 ng mL−1 | |||||||
| <30 ng mL−1 (referent) | 43 | 1 | 1 | 1 | 1 | 1 | 1 |
| ≥30 ng mL−1 | 39 | 1.41 (0.95, 2.09) | 1.44 (0.99, 2.11) | 1.27 (0.84, 1.92) | 1.25 (0.85, 1.84) | 1.34 (0.84, 2.13) | 1.25 (0.81, 1.92) |
a8 twin gestations contributed two observations each to the analysis.
bRRs and 95% CIs calculated using multiply-imputed generalized estimating equations of log-binomial regression with robust standard errors and stabilized inverse-probability weights to account for loss to follow-up. Poisson models used in cases of model non-convergence.
cModels further weighted to account for selection of pregnancies.
dModels further weighted to account for selection of pregnancies and survival to live birth.
eNumber of live-born males.
fMultivariable model adjusted for age (continuous), race/ethnicity (white or non-white), number of previous live births (0, 1, or ≥2).